Although LRRK2 kinase inhibitors have proven protective in experimental parkinsonism and have been suggested for clinical translation [146], the mechanisms by which mutant LRRK2 contributes to PD pathophysiology are not fully understood. The gene discussed is LRRK2; the disease is Parkinsonism.